EUVIMEDEUVIMED entdecken
Crossref

Clostridioides difficile Infection: Emerging Challenges and the Rise of Microbiome-Targeted Therapeutics

Microbial Bioactives · 01.04.2026 · 9 (1) · 1-13

DOI: 10.25163/microbbioacts.9110623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Bioactives, online erschienen am 01.04.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile infection (CDI) continues to represent a major global healthcare challenge, driven by increasing incidence, high recurrence rates, and the emergence of hypervirulent strains. Traditionally considered an antibiotic-associated infection, CDI is now recognized as a complex disease shaped by interactions among microbial ecology, host immunity, and pathogen virulence. Conventional treatments, including metronidazole, vancomycin, and fidaxomicin, primarily target vegetative bacterial cells but do not fully eradicate dormant spores or restore the disrupted intestinal microbiome. As a result, recurrence occurs in a substantial proportion of patients, highlighting the limitations of antibiotic-centered management strategies. Recent advances in microbiome research have shifted attention toward ecological restoration of the gut microbial community as a key therapeutic objective. Evidence from clinical trials and meta-analyses demonstrates that microbiome-targeted interventions—particularly fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs)—can significantly reduce recurrence by restoring microbial diversity and reestablishing colonization resistance. These therapies promote functional recovery of microbial metabolism, including bile acid transformation pathways that inhibit C. difficile spore germination. Adjunctive approaches are also emerging, such as monoclonal antibodies targeting toxin B, nanoparticle-based drug delivery systems, and synthetic antimicrobial polymers designed to suppress toxin activity and prevent spore outgrowth. Collectively, these developments suggest a paradigm shift in CDI management—from pathogen eradication alone to integrated strategies that restore microbial ecosystem stability. Understanding the dynamic interactions between host immunity, microbial community structure, and bacterial virulence factors will be essential for developing next-generation therapies. Future research should focus on optimizing microbiome-based interventions, improving therapeutic standardization, and evaluating long-term safety to establish sustainable and personalized treatment strategies for CDI.

Zitieren

APA

(2026). Clostridioides difficile Infection: Emerging Challenges and the Rise of Microbiome-Targeted Therapeutics. Microbial Bioactives, 9(1), 1-13. https://doi.org/10.25163/microbbioacts.9110623

Vancouver

Clostridioides difficile Infection: Emerging Challenges and the Rise of Microbiome-Targeted Therapeutics. Microbial Bioactives. 2026;9(1):1-13. doi:10.25163/microbbioacts.9110623

BibTeX
@article{euvimed2026,
  title = {Clostridioides difficile Infection: Emerging Challenges and the Rise of Microbiome-Targeted Therapeutics},
  journal = {Microbial Bioactives},
  year = {2026},
  volume = {9},
  number = {1},
  pages = {1--13},
  doi = {10.25163/microbbioacts.9110623}
}
Kostenlos starten →